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Objective. To test the hypothesis that, in the initial evaluation of patients with suspected
coronary artery disease (CAD), stress myocardial perfusion imaging (MPI) would result in less
downstream testing than coronary computed tomographic angiography (CCTA).
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Methods. In this international, randomized trial, mildly symptomatic patients with an
intermediate likelihood of having CAD, and asymptomatic patients at intermediate risk of
cardiac events, underwent either initial stress-rest MPI or CCTA. The primary outcome was
downstream noninvasive or invasive testing at 6 months. Secondary outcomes included
cumulative effective radiation dose (ERD) and costs at 12 months.
Results. We recruited 303 patients (151 MPI and 152 CTA) from 6 centers in 6 countries.
The initial MPI was abnormal in 29% (41/143) and CCTA in 56% (79/141) of patients. Fewer
patients undergoing initial stress-rest MPI had further downstream testing at 6 months (ad-
justed OR 0.51, 95% CI 0.28-0.91, P 5 0.023). There was a small increase in the median
cumulative ERD with MPI (9.6 vs. 8.8 mSv, P 5 0.04), but no difference in costs between the
two strategies at 12 months.
Conclusion. In the management of patients with suspected CAD, a strategy of initial stress
MPI is substantially less likely to require further downstream testing than initial testing with
CCTA. Trial registration: clinicaltrials.gov identification number NCT01368770. (J Nucl
Cardiol 2016)
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Abbreviations
MPI Myocardial perfusion imaging
CCTA Coronary computerized tomography
angiography
CAD Coronary artery disease
IAEA International Atomic Energy Agency
ATP III Adult Treatment Program III
CMR Cardiac magnetic resonance
ECG Electrocardiogram
NYHA New York Heart Association
ERD Effective radiation dose
INTRODUCTION
Functional testing by stress myocardial perfusion
imaging (MPI) and anatomical imaging by coronary
computed tomography angiography (CCTA) are often
used interchangeably in the initial evaluation of patients
suspected to have coronary artery disease (CAD). In
patients with an intermediate likelihood of having CAD,
the results of functional testing provide important
diagnostic and prognostic information. This information
is usually sufficient to determine the need for further
invasive testing and revascularization.1 Coronary CTA
provides accurate anatomical information regarding the
extent and severity of CAD.2,3 But this often needs to be
supplemented by the documentation of typical symp-
toms, or the objective demonstration of ischemia by
further testing, before management decisions can be
made. Moreover, the mere identification of anatomical
stenosis may often lead to revascularization without the
assessment of its functional significance.4 Therefore, a
strategy of initial evaluation by CCTA may result in
greater downstream testing and revascularization, result-
ing in increased healthcare costs.3,5 On the other hand,
CCTA may also detect the presence of hemodynami-
cally insignificant coronary lesions which may be
prognostically important,6 and although unproven, may
potentially benefit from intensive medical treatment.
Data from randomized controlled trials comparing stress
MPI and CCTA as initial tests in this patient population
are only recently becoming available,7,8 and current
practice guidelines do not strongly prefer one modality
of testing over the other.9,10
We performed an international, multi-centric, random-
ized controlled trial to evaluate the effect of initial testing
with stress MPI or CCTA on the use of further downstream
testing in patients with suspected CAD. We also compared
the costs of the two strategies and the effective radiation
dose to patients. Our primary hypothesis was that the initial
use of stress-rest MPI would result in less additional
noninvasive and invasive testing in the short term.
METHODS
Study design
This was an open-label, parallel-arm, multi-center, ran-
domized trial, conducted at 6 tertiary care hospitals in 6
countries (Brazil, Czech Republic, India, Mexico, Slovenia,
and Turkey) chosen on the basis of expertise in both nuclear
imaging and radiology. Randomization was stratified by site
and participants’ symptom status (asymptomatic or symp-
tomatic). The study protocol was approved by the ethics
committees at all participating sites and all patients provided
written informed consent. The study was funded by the
See related editorials, doi:10.1007/s12350-016-
0683-0, doi:10.1007/s12350-016-0702-1, and
doi:10.1007/s12350-016-0710-1.
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International Atomic Energy Agency through a Coordinated
Research Project (IAEA-CRP E.1.30.38). The funding agency
provided logistic support during the design and conduct of the
study but was not involved in the data analysis, interpretation,
or the decision to publish. The manuscript was drafted by the
lead author with inputs from all investigators and technical
experts from the IAEA.
Participants
Consenting patients above 21 years, who were mildly
symptomatic (those in class II NYHA) and had an intermediate
likelihood of having CAD,11 or asymptomatic patients who
were determined to be at intermediate or high risk of coronary
events by the Framingham (ATP III) criteria, were eligible to
participate. Patients were recruited by treating cardiologists at
the outpatient clinics of the participating hospitals. We
excluded patients with known CAD, documented either by
invasive or non-invasive imaging, a history of myocardial
infarction (MI) or coronary revascularization. We also exclu-
ded patients who were severely symptomatic (class III or IV
NYHA), had chronic renal impairment precluding contrast
injection, severe medical disease with limited life-expectancy,
known contraindication or allergy to pharmacologic stress
agents or contrast agents, or had an abnormal cardiac rhythm
(including persistent atrial fibrillation) which precluded ECG
gating. Very obese patients were excluded because of weight
limitations imposed by scanner design. We did not include
pregnant or lactating women.
Randomization
A random sequence of blocks of varying sizes (4 and 6)
stratified by site and symptom status (symptomatic or asymp-
tomatic) was generated using a freely available online random
sequence generator (www.randomization.com) by the study
statistician at the data management and statistical unit
(DMSU), Indian Institute of Public Health-Delhi, India. Allo-
cation was concealed using sequentially numbered, sealed
opaque envelopes. Envelopes were prepared by the statistician
and sent by post to the recruiting sites. The envelopes con-
tained randomization forms that were completed by the
investigator and emailed to the DMSU within 24 hours of
randomization. As part of the effort to minimize bias, baseline
data including physician preference for either test were
recorded after consent was obtained, prior to randomization.
Once the allocated diagnostic procedure was known, the
patient and referring physician were informed and the proce-
dure was scheduled in consultation with the radiologist or
nuclear physician.
Diagnostic imaging
Stress-rest MPI and CCTA were performed and inter-
preted by expert nuclear physicians, cardiologists, or
radiologists on site. Choice of exercise protocol or pharmaco-
logic stressor agent was left to physician discretion. Images
were processed using standard commercially available soft-
ware. Stress MPI studies were categorized as normal,
abnormal, or inconclusive by the reporting nuclear physician.
The presence of any perfusion defect (either at rest or stress) or
wall motion abnormality (not explained by left bundle branch
block) was considered abnormal. In addition, perfusion data
were recorded using a 17-segment model and perfusion
abnormalities were quantitated using summed scores. Physi-
cians adhered to standard procedures and guideline
recommendations while performing stress testing, image
acquisition, interpretation, and reporting.12–14
Coronary CTA studies were performed using a multide-
tector scanner (64-slice or greater), and reported in accordance
with current practice guidelines.15,16 Calcium scoring was
performed prior to contrast injection. Studies were reported as
being normal, if there were no coronary stenoses or any
luminal narrowing was less than 30% of the reference vessel
diameter. Stenoses were categorized as being mild (30%-49%),
moderate (50%-69%), or severe (C70%).
Data management
All data were entered at participating sites into
editable PDF forms with built-in quality checks. The forms
were transmitted electronically to the data management center
at the Indian Institute of Public Health-Delhi, where the data
were exported into statistical analysis software using a
customized form management system.
Study outcome measures
The primary outcome was the proportion of patients
having additional non-invasive testing with another modality
(rest-stress MPI, CCTA, stress ECG, CMR, or stress ECHO),
or invasive coronary angiography within 6 months of initial
testing.
Secondary outcomes were as follows: (1) Proportion of
patients who had planned, elective invasive angiography at 6-
month follow-up; (2) proportion of patients who had planned,
elective coronary interventions or bypass surgery at 1-year
follow-up; (3) the occurrence of a composite of all-cause
mortality, nonfatal MI, recurrent ischemia, or unplanned
coronary revascularization at 1-year follow-up; (4) cumulative
effective radiation dose (ERD) to patients at 12 months; and
(5) total cost of the two strategies at 12 months.
To minimize bias, investigators were explicitly discour-
aged from performing additional testing with another modality
merely to comply with physician preference or local practices.
The following were considered acceptable indications for
additional non-invasive testing with another modality: (i)
Negative initial test, but high clinical suspicion of CAD; (ii)
inconclusive initial test result; and (iii) positive initial test, but
low clinical suspicion (suspected false positive). As the
preference of the referring cardiologist for either of the tests
may be an important determinant of further downstream
testing, we also adjusted for this variable in the primary
analysis. Invasive coronary angiography could be performed in
the event of a (i) Positive test (for delineation of anatomy and
planning revascularization), (ii) negative initial test but high
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clinical suspicion, (iii) inconclusive initial test result, (iv)
positive initial test but low clinical suspicion (suspected false
positive, to rule out CAD).
Statistical analysis
Wehypothesized that either of the strategieswould result in
20% of patients receiving a second non-invasive test or coronary
angiography during the first 6 months after enrolment. We
assumed that we would be able to identify 10-15 sites contribut-
ing about 30-40 participants each. We determined that with 500
patients, we would be able to detect a 15% absolute increase in
the proportion of patients having a second non-invasive test or
coronary angiography between the two strategies, with over 90%
power at an alpha level of 0.05, after accounting for a 10% rate of
post-randomization loss to follow-up (see SupplementaryMate-
rial Table 4). However, 7 of the planned 13 sites were not
granted ethics or regulatory approval. Further, recruitment rates
were lower than expected at most participating sites. The study
was stopped due to lack of funding at the end of 3 years after
enrolment of 303 patients, without knowledge of the study
outcomes. Given that we had only 2% loss to follow-up, this
sample size retains 83% power to detect the anticipated
difference in the primary outcome between the study groups.
Descriptive statistics are presented for all variables col-
lected at baseline. The primary analysis was by intention-to-
treat. In this analysis, all patients whose outcome data were
available were included in the arm to which they were random-
ized, irrespective of the diagnostic procedure received. A per-
protocol analysis for the primary outcomes was also performed
excluding those who did not undergo the allocated diagnostic
procedure, or underwent the procedure 180 days after random-
ization. The primary outcome was analyzed using logistic
regression adjusted for the stratifying factors (site and symptom
Table 1. Baseline characteristics
Characteristics MPI arm (n 5 151) CCTA arm (n 5 152) P value
Age in years 60.2 (11.7) 58.9 (11.1) 0.26
Males 70 (46.4) 75 (49.3) 0.60
Ethnicity
Caucasian 104 (68.9) 111 (73.0)
Hispanic 37 (24.5) 31 (20.4)
Indian 8 (5.3) 8 (5.3) 0.72
African 2 (1.3) 1 (0.7)
Other 0 (0.00) 1 (0.7)
BMI 29.0 (9.8) 27.6 (4.4) 0.11
Diabetes 43 (28.5) 43 (28.3) 0.97
Hypertension 97 (64.2) 97 (63.8) 0.94
Smoking 25 (16.6) 36 (23.7) 0.12
Family history of CAD 45 (29.8) 48 (31.6) 0.74
Dyslipidemia 83 (55.0) 89 (58.6) 0.53
Aspirin 76 (50.3) 72 (47.4) 0.61
Statins 76 (50.3) 72 (47.4) 0.61
Beta blockers 62 (41.1) 69 (45.4) 0.45
ACE inhibitors/ARBs 80 (53.0) 90 (59.2) 0.28
Nitrates 21 (16.0) 14 (10.7) 0.20
Diuretics 37 (24.5) 37 (24.3) 0.97
Clopidogrel 6 (4.0) 7 (4.6) 0.79
Calcium channel blocker 26 (17.2) 22 (14.5) 0.51
Antiarrhythmic agents 16 (10.6) 15 (9.9) 0.83
Symptomatic 134 (88.7) 137 (90.1) 0.69
Angina 121 122
Dyspnea or other ischemic symptoms 13 15
Non-invasive test preferred by treating physician
Stress MPI 34 (22.5) 27 (17.8)
CCTA 17 (11.3) 15 (9.9)
No preference 100 (66.2) 110 (72.4) 0.50
All continuous variables are reported as mean (standard deviation) and categorical variables as frequency (%)
MPI Myocardial perfusion imaging; CCTA Coronary computed tomographic angiography; BMI body mass index, CAD coronary
artery disease; ACE angiotensin converting enzyme; ARB angiotensin receptor blocker
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status) and the stated preference of the treating cardiologist.
Odds ratios (OR) and their 95% confidence intervals were
computed. Similar analyses were performed for the secondary
outcomes. Radiation exposure to each patient undergoing MPI
(ERD, effective radiation dose in mSv) was calculated based on
the radiopharmaceutical administered and their activities
(MBq), as per the most recent recommendations of the Interna-
tional Commission on Radiological Protection.17,18 For patients
undergoing CCTA, ERDwas calculated as a product of the dose
length product and an organ weighting factor for the chest in
accordance with the current recommendations.17 For coronary
angiography and angioplasty, average ERD values were
obtained from the published literature. We used the DRG data
from theSlovenian public health system to estimate unit costs for
all procedures. Total cost was estimated by addition of direct and
indirect costs (data obtained from 49 patients undergoing
diagnostic testing at the University Medical Centre, Ljubljana).
A P value of 0.05 was considered significant. All analyses were




Between June 2011 and 2014, we randomized 303
patients (271, 89.4% symptomatic) at 6 tertiary care
hospitals in 6 countries. (Figure 1, Supplementary
Material Table 1) The baseline characteristics of inclu-
ded patients were similar in both arms (Table 1). On the
average, patients were about 60 years of age, were
predominantly male, were overweight, and had a high
burden of risk factors for CAD. Notably, nearly 30% of
the patients were diabetic, a similar proportion had a
family history of premature CAD, nearly 2/3rd were
hypertensive, and over half had dyslipidemia. Of the
symptomatic patients, chest pain (typical, atypical, or
non-anginal) was the commonest symptom (243/271,
90%). Most cardiologists did not have a strong prefer-
ence for one initial test over the other (Table 1).
Initial testing
Hundred and fifty-one patients were randomized to
the MPI arm and 152 to the CCTA arm, and 95%
underwent testing as allocated (289/303). Details of the
study procedures are provided in the Supplementary
Material (Representative images in Figures 2 and 3).
Most patients had normal initial test results. Forty-one of
143 (29%) patients had an abnormal stress MPI and one
patient had an inconclusive result. Of those with
Figure 1. Enrolment, randomization, and follow-up of trial participants. MPI Myocardial
perfusion imaging, CCTA coronary CT angiography.
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abnormal MPI results, 14 (10%) had reversible perfusion
defects involving[10% of the LV myocardium and the
remaining had less severe defects. An abnormal initial
CCTA was reported in 79/141 (56%) patients. Of these,
25 (18%) had at least one lesion with C70% diameter
stenosis, and 21 (18%) had intermediate lesions (50%-
69% diameter stenosis). The median calcium score was
6.7 units with 75% of the patients having a score\97
(Supplementary Material Tables 2, 3).
Outcomes
Follow-up of at least 6 months was available for
297 (98%) patients. Two patients in the MPI arm and 3
in the CCTA arms were lost to follow-up, and 1 died.
One patient was excluded from the analysis as an MPI
study had been performed prior to randomization.
(Figure 1) Patients undergoing stress MPI as the initial
test were half as likely (adjusted OR 0.51, 95% CI 0.28-
0.91, P = 0.023) as those undergoing CCTA to have the
primary outcome. The per-protocol analysis showed
similar results (Table 2). In exploratory analyses, the
results were consistent (interaction P values in paren-
theses) across subgroups defined by symptom status
(P = 0.6), angina as presenting symptom (P = 0.71),
presence of diabetes (P = 0.18), and participating site
(P = 0.10). The difference in the primary outcome was
driven largely by the performance of further non-
invasive testing to determine the significance of lesions
detected on CCTA (Tables 2, 3). Of the 26 patients who
Figure 2. A 73-year-old male with exertional dyspnea and a positive family history of coronary
artery disease was randomized to undergo exercise MPI. Stress (top) and rest (bottom) Tc-99 m
tetrofosmin myocardial perfusion images demonstrate reversible ischemia in the apex, apical
segment of the anterior wall, and apical segment of the lateral wall. MPI myocardial perfusion
imaging.
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underwent repeat non-invasive testing in the CCTA arm,
23 underwent stress MPI. One patient each underwent
stress echo, exercise ECG, and cardiac MRI. In the MPI
arm, 5 patients underwent a CCTA and 2 underwent
repeat MPI after pharmacologic stress. Downstream
performance of invasive coronary angiography was not
different between the two arms. Most coronary angio-
grams were done in patients with a positive initial test
for the purpose of delineating anatomy and planning
revascularization (15/18 in the MPI arm and 20/21 in the
CCTA arm).
There were no significant differences in the pro-
portion of patients undergoing coronary angiography at
6 months or any revascularization procedure at
12 months (Table 2). One patient in the CCTA arm
died during the follow-up. Two patients in the MPI arm
and one in the CCTA arm had recurrent ischemia. One
additional patient in the MPI arm underwent unplanned
PCI. Overall, the composite of death, nonfatal MI,
recurrent ischemia, or unplanned revascularization
occurred in 3 (2.3%) patients in the MPI arm and 2
(1.6%) in the CCTA arm.
The median ERD to patients was significantly
greater with the initial stress MPI than CCTA (a
difference of over 4 mSv). But this difference reduced
substantially at 12 months because of more downstream
testing in the CCTA arm (Table 4).
The cost of the initial CCTA was marginally greater
than stress MPI (€ 719 vs. 699). However, at 12 months,
the average cost per patient was not significantly
different between the two arms (€ 1365 vs. 1243,
P = 0.54) (Supplementary Material Table 5).
DISCUSSION
The results of this diagnostic randomized trial
suggest that in patients with an intermediate likelihood
of having CAD, and in those at intermediate or high risk
of coronary events, initial evaluation with stress MPI
results in substantially less downstream non-invasive
and invasive testing before decisions regarding man-
agement can be made. There was no difference in costs
between the two approaches, but patients evaluated with
initial stress-rest MPI received a small but significantly
greater cumulative exposure to radiation at 1-year.
These results are based on a multi-ethnic population of
patients, with a large proportion drawn from emerging
economies.
We believe that the validity of these results is
enhanced by two important considerations. First, deci-
sion-making regarding downstream test use was
standardized and pre-specified, and effect-estimates
were adjusted for physician preference (for either of
the diagnostic modalities), thereby minimizing bias in
Figure 3. A 68-year-old diabetic male patient with atypical symptoms underwent CCTA which
showed a calcium score of 640 Agatston and a partially calcified proximal LAD plaque, causing
moderate stenosis (1A -LAD curved multiplanar reconstruction). Subsequent exercise stress MPI
revealed severe ischemia (arrows) in the anterior wall, antero lateral region and apex (1B). MPI
myocardial perfusion imaging, CCTA coronary CT angiography, LAD left anterior descending
coronary artery.
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this diagnostic randomized trial. Second, investigators
used contemporary diagnostic equipment and adhered to
currently recommended guidelines while performing
and reporting test results, thereby reflecting current best
practice.
Increased downstream testing with CCTA
The results of our study are consistent with those
from the previous observational and randomized studies.
In a systematic review, Nielsen et al3 identified 6
observational studies and one small randomized trial7
which compared initial functional and anatomical eval-
uation and reported on downstream test utilization.
Combining these results in a meta-analysis, these
authors showed that a strategy of initial coronary CTA
resulted in greater use of further downstream testing and
coronary angiography compared to initial testing with
either MPI or exercise ECG (24.4% vs. 18.5%; OR 1.38,
95% CI 1.33-1.43; P = 0.0001). The tendency for
patients evaluated initially by CCTA to increase the
likelihood of downstream coronary angiography (and
revascularization) has also been observed in the context
of low-risk patients with acute chest pain.19,20 However,
a more recent randomized trial comparing exercise ECG
with CCTA in patients with stable chest pain showed a
greater use of downstream non-invasive testing in the
exercise ECG arm.21 This was attributable to the large
number of inconclusive exercise ECG results (66/245,
27%). The diagnostic performance of exercise ECG is
inferior to stress MPI22 and is perhaps not the modality
of choice in a comparative evaluation between anatom-
ical and functional testing.
Downstream testing and coronary
revascularization
Much of the increase in downstream testing in the
CCTA arm in our study was because of physician
uncertainty regarding the relationship between the
anatomic lesions seen on CCTA and patient symptoms.
The difference in rates of downstream testing was driven
primarily by the performance of additional non-invasive
tests; there was no difference in the rates of coronary
angiography unlike in the previous studies.3,8,23 This
may reflect local practices such as a preference for
obtaining information from further non-invasive testing
rather than from fractional flow reserve (FFR) measure-
ment at angiography.
The increase in rates of coronary angiography also,
predictably, increased the rates of revascularization in
the CCTA arm in the previous studies. The OR for
revascularization with CCTA was 2.6 (2.5-2.77) in the
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Multicenter Imaging Study for Evaluation of Chest Pain
(PROMISE) trial, the rate of revascularization with
CCTA was nearly twice that with functional testing
(6.2% vs. 3.2%).8 We were unable to show any
differences in revascularization rates between the two
arms perhaps because of a preference for functional
testing to decide on significance of lesions, and also
partly because of resource constraints limiting the
performance of revascularization (in at least 3 of the
participating countries, Mexico, India, and Brazil, a
large proportion of healthcare spending is out-of-
pocket). However the impact of the choice of initial
test (and resulting differences in rates of revasculariza-
tion) on clinical outcomes is unclear. While some
studies3,24 have suggested a reduction in myocardial
infarction with a strategy of initial testing with CCTA,
the large PROMISE trial and a recent meta-analysis of
observational studies of CCTA and MPI did not show
any difference in hard clinical outcomes.8,25
Effect on radiation exposure and costs
Advances in CT scanner design and improved
protocols for image acquisition and analysis have
reduced radiation exposure to patients. Expectedly, the
median ERD in the CCTA arm was substantially less
than that with MPI. However, this difference was
attenuated by the greater need for further testing in the
CCTA arm by 6 months. But as only a minority of
patients in such a cohort are likely to undergo further
testing or revascularization by PCI, the distribution of
radiation exposure is likely to be complex, and the
median ERD may not be a representative measure.
Nevertheless, cumulative ERD data from our study are
similar to that reported in PROMISE, although the ERD
was greater in the CCTA arm in that study.8
There were no significant differences in costs
between the two strategies. Two previous studies
reporting on comparative costs found initial evaluation
Table 4. Effective radiation dose to patients
Effective radiation dose (ERD) in mSv MPI arm CCTA arm P value
Initial diagnostic procedure (n = 143) (n = 142)
Median ERD (IQR) 9.3 (8.5, 9.7) 5.0 (3.8, 10) \0.001
All diagnostic procedures at 12 months (n = 143) (n = 145)
Median ERD (IQR) 9.6 (8.9, 12.5) 8.8 (4, 13.2) 0.040
All diagnostic and therapeutic procedures* at 12 months (n = 143) (n = 145)
Median ERD (IQR) 9.6 (8.9, 12.5) 8.8 (4, 13.2) 0.041
* Patients who underwent angiography and percutaneous coronary angioplasty (PCI) at the same time, the dose of PCI was used
for calculating the ERD
 For 24 patients in the CCTA and 16 in the MPI arm, 12- month data were unavailable. ERD was estimated from 6-month data for
these patients
 P value reported is for the Wilcoxon rank-sum test for the difference in median ERD values





Non-invasive testing at 6 months 7 (4.7) 26 (17.6)
Negative initial test, but high clinical suspicion 2* 4
Inconclusive initial test result 2 21
Positive initial test, but low clinical suspicion (suspected false
positive)
3 1
* One patient had a dilated left ventricle and another had an equivocal perfusion defect (both studies were reported as normal)
 One patient had multiple mild lesions and the others were suspected to have microvascular disease causing angina. All 4
patients had normal subsequent non-invasive test results. No patient had coronary angiography
 This group includes 10 patients with severe (C70% diameter stenosis), 5 with intermediate (50%-69% stenosis), and 2 with mild
(30%-49%) lesions where the clinician was uncertain about the relationship of the lesions to symptom status. This group also
includes one patient with a myocardial bridge involving the left anterior descending artery and 3 patients who could not
complete the procedure (2 because of very high calcium scores and 1 because of an allergic reaction to contrast agent)
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with CCTA to be cost saving,26,27 but the initial
functional test in these analyses was exercise ECG with
its inherently high rate of inconclusive results mandating
further testing for decision making.
Limitations
Our study has several limitations. First, it was
prematurely stopped with only 60% of the planned
sample recruited and the large effect size seen may
therefore reflect a ‘‘random-high.’’ However, our esti-
mates remained stable on adjustment and are likely to
indicate a true effect. Second, even though we made
efforts to minimize bias both at the design and analysis
stage, it is impossible to rule out its effect on physician-
driven outcomes in an open-label study. Third, we did
not use a central core lab and relied on site-reported test
results. Fourth, our study was not powered to detect
differences in clinical outcomes which could potentially
result from the differences in the rates of downstream
testing. Finally, we did not capture information relating
to changes in symptom status or medical therapy during
the course of follow-up, which may have provided
additional insights into the utility of either of the two
strategies.
CONCLUSIONS
In the initial evaluation of patients with suspected
CAD, a strategy of functional testing with stress-rest
MPI compared to CCTA, may result in less downstream
testing, but with a small increase in radiation exposure to
patients. These results must be taken into consideration
when choosing the initial test for the evaluation of
patients with suspected CAD.
NEW KNOWLEDGE GAINED
In patients with suspected CAD, initial testing with
coronary CTA compared to stress-rest MPI may result in
greater downstream test utilization before clinical deci-
sions can be made. Patients being evaluated for
suspected CAD should be made aware of the potentially
greater requirement for further testing if coronary CTA
is used in the initial evaluation
Disclosures
None of the authors have any relevant conflicts of
interest.
Funding
The International Atomic Energy Agency.
Open Access
This article is distributed under the terms of the Creative
Commons At tr ibut ion 4.0 Internat ional License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any med-
ium, provided you give appropriate credit to the original au-
thor(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS.
Comparison of the short-term survival benefit associated with
revascularization compared with medical therapy in patients with
no prior coronary artery disease undergoing stress myocardial
perfusion single photon emission computed tomography. Circu-
lation. 2003;107:2900–7.
2. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR,
van Mieghem CA, et al. Diagnostic accuracy of 64-slice computed
tomography coronary angiography: a prospective, multicenter,
multivendor study. J Am Coll Cardiol. 2008;52:2135–44.
3. Nielsen LH, Ortner N, Norgaard BL, Achenbach S, Leipsic J,
Abdulla J. The diagnostic accuracy and outcomes after coronary
computed tomography angiography vs. conventional functional
testing in patients with stable angina pectoris: a systematic review
and meta-analysis. Eur Heart J Cardiovasc Imaging. 2014;15:961–
71.
4. Topol EJ, Nissen SE. Our preoccupation with coronary luminol-
ogy: The dissociation between clinical and angiographic findings
in ischemic heart disease. Circulation. 1995;92:2333–42.
5. Shreibati JB, Baker LC, Hlatky MA. Association of coronary CT
angiography or stress testing with subsequent utilization and
spending among Medicare beneficiaries. JAMA. 2011;306:2128–
36.
6. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff
MJ, et al. Age- and sex-related differences in all-cause mortality
risk based on coronary computed tomography angiography find-
ings results from the international multicenter CONFIRM
(coronary CT angiography evaluation for clinical outcomes: An
international multicenter registry) of 23854 patients without
known coronary artery disease. J Am Coll Cardiol. 2011;58:849–
60.
7. Min JK, Koduru S, Dunning AM, Cole JH, Hines JL, Greenwell D,
et al. Coronary CT angiography versus myocardial perfusion
imaging for near-term quality of life, cost and radiation exposure:
A prospective multicenter randomized pilot trial. J Cardiovasc
Comput Tomogr. 2012;6:274–83.
8. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR,
Cavanaugh B, et al. Outcomes of anatomical versus functional
testing for coronary artery disease. N Engl J Med. 2015;372:1291–
300.
9. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas
AP, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline
for the diagnosis and management of patients with stable ischemic
heart disease: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines, and the American College of Physicians, American
Association for Thoracic Surgery, Preventive Cardiovascular
Nurses Association, Society for Cardiovascular Angiography and
Interventions, and Society of Thoracic Surgeons. J Am Coll Car-
diol. 2012;60:e44–164.
Karthikeyan et al. Journal of Nuclear Cardiology
Functional or anatomical imaging for CAD
10. Task Force M, Montalescot G, Sechtem U, Achenbach S,
Andreotti F, Arden C, et al. ESC guidelines on the management of
stable coronary artery disease: The task force on the management
of stable coronary artery disease of the European Society of
Cardiology. Eur Heart J. 2013;2013(34):2949–3003.
11. Diamond GA, Forrester JS. Analysis of probability as an aid in the
clinical diagnosis of coronary-artery disease. N Engl J Med.
1979;300:1350–8.
12. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC,
DiFilippo FP, et al. Single photon-emission computed tomogra-
phy. J Nucl Cardiol. 2010;17:941–73.
13. Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao S-S.
Stress protocols and tracers. J Nucl Cardiol. 2009;16:331.
14. Tilkemeier PL, Cooke CD, Grossman GB Jr, Ward RP. Stan-
dardized reporting of radionuclide myocardial perfusion and
function. J Nucl Cardiol. 2009;16:650.
15. Raff GL, Abidov A, Achenbach S, Berman DS, Boxt LM, Budoff
MJ, et al. SCCT guidelines for the interpretation and reporting of
coronary computed tomographic angiography. J Cardiovasc
Comput Tomogr. 2009;3:122–36.
16. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS,
et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert
Consensus Document on Coronary Computed Tomographic
AngiographyA Report of the American College of Cardiology
Foundation Task Force on Expert Consensus Documents. J Am
Coll Cardiol. 2010;55:2663–99.
17. Cousins C, Miller DL, Bernardi G, Rehani MM, Schofield P, Vano
E, et al. ICRP PUBLICATION 120: Radiological protection in
cardiology. Ann ICRP. 2013;42:1–125.
18. Radiation dose to patients from radiopharmaceuticals: A fourth
addendum to ICRP Publication 53. http://www.icrp.org/docs/
Radiation20Dose20to20Patients20from20Radiopharmaceuticals
20-20A20fourth20addendum20to20ICRP20Publication2053.pdf.
Accessed 23 June 2016.
19. Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di
Carli MF, et al. Outcomes after coronary computed tomography
angiography in the emergency department: A systematic review
and meta-analysis of randomized, controlled trials. J Am Coll
Cardiol. 2013;61:880–92.
20. Uretsky S, Argulian E, Supariwala A, Agarwal SK, El-Hayek G,
Chavez P, et al. Comparative effectiveness of coronary CT
angiography vs. stress cardiac imaging in patients following hos-
pital admission for chest pain work-up: The prospective first
evaluation in chest pain (PERFECT) trial. J Nucl Cardiol.
2016;8:1–201.
21. McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, Trinick
TR, et al. A comparison of cardiac computerized tomography and
exercise stress electrocardiogram test for the investigation of
stable chest pain: The clinical results of the CAPP randomized
prospective trial. Eur Heart J Cardiovasc Imaging. 2015;16:441–8.
22. Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA,
Friedman J, et al. Exercise myocardial perfusion SPECT in
patients without known coronary artery disease: Incremental
prognostic value and use in risk stratification. Circulation.
1996;93:905–14.
23. Skelly AC, Hashimoto R, Buckley DI, Brodt ED, Noelck N,
Totten AM et al. Noninvasive Testing For Coronary Artery Dis-
ease. Rockville (MD);2016.
24. Investigators S-H.CT coronary angiography in patientswith suspected
angina due to coronary heart disease (SCOT-HEART): an open-label,
parallel-group, multicentre trial. Lancet 2015;385:2383–91.
25. Cantoni V, Green R, Acampa W, Petretta M, Bonaduce D, Sal-
vatore M, et al. Long-term prognostic value of stress myocardial
perfusion imaging and coronary computed tomography angiogra-
phy: A meta-analysis. J Nucl Cardiol. 2016;23:185–97.
26. Nielsen LH, Olsen J, Markenvard J, Jensen JM, Norgaard BL.
Effects on costs of frontline diagnostic evaluation in patients
suspected of angina: Coronary computed tomography angiography
vs. conventional ischaemia testing. Eur Heart J Cardiovasc
Imaging. 2013;14:449–55.
27. Genders TS, Ferket BS, Dedic A, Galema TW, Mollet NR, de
Feyter PJ, et al. Coronary computed tomography versus exercise
testing in patients with stable chest pain: Comparative effective-
ness and costs. Int J Cardiol. 2013;167:1268–75.
Journal of Nuclear Cardiology Karthikeyan et al.
Functional or anatomical imaging for CAD
